Top Story

Commission approves ledipasvir/sofosbuvir combo for marketing in EU

November 20, 2014

The European Commission granted marketing authorization to Gilead Sciences for its once-daily single tablet regimen of Harvoni for the treatment of adults with chronic hepatitis C genotype 1 and 4 infection, according to a company news release.

The authorization, following an accelerated assessment by the European Medicines Agency, allows for Harvoni (ledipasvir/sofosbuvir), to be marketed in all 28 EU nations, the release said.

In the Journals

Dracunculiasis cases continue to decline

November 20, 2014
The number of worldwide dracunculiasis cases has greatly declined during the past few years, according to recent findings in MMWR. Also known as Guinea worm disease…
In the Journals

Global vaccination coverage progressing, requires further improvement

November 20, 2014
Global vaccination coverage is progressing promisingly, but requires further improvement to ensure all children are protected from vaccine-preventable diseases…
Check Hep C program effective in identifying HCV in New York Meeting News CoveragePerspective

Check Hep C program effective in identifying HCV in New York

November 20, 2014
BOSTON — The Check Hep C program, a community-based initiative in New York that focuses on finding and testing individuals with hepatitis C virus infection in…
More News Headlines »
CME
j64a_activity

CRITICAL ISSUES IN HBV: Considerations in Optimizing HBV Treatment

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

Hepatitis B virus (HBV) infection is a global epidemic with a worldwide burden. Physicians must address the importance…
More »
Meeting News Coverage Video
thumbnail for video 3895262652001

Early liver transplantation could improve survival rates for patients with alcoholic hepatitis

November 17, 2014
BOSTON — Ibrahim A. Hanouneh, MD, hepatologist at Cleveland Clinic, discussed results of a study that compared…
More »
CME
J490 Challenges in HIV Screening

Challenges in HIV Screening and Prophylaxis: PrEP’ing for the Future

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

A substantial proportion of Americans with HIV remain undiagnosed and suboptimally treated. Failure to follow…
More »
morganatic-roan